Precision BioSciences (DTIL) revenue breakdown
By segment, Therapeutics is the largest at 97% of fiscal 2021 revenue, growing 127% a year over 3 years.
Revenue by segment
Fiscal years, as Precision BioSciences reports them in its 10-K filings; fiscal 2021 total $116M.
| Segments | 2018 | 2019 | 2020 | 2021 | Share |
|---|---|---|---|---|---|
| Therapeutics | $10M | $21M | $22M | $112M | 97% |
| Food | $1M | $2M | $2M | $4M | 3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DTIL.
Open DTIL in InvestinglyQuestions
Where does Precision BioSciences make its money?
In fiscal 2021, by segment: Therapeutics $112M, Food $4M.
From Precision BioSciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.